Clinic offers health-alert Pill
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A leading family planning centre says it is continuing to offer women aged over 30 the brands of oral contraceptive Pill that were the subject of a Government alert last week.
Professor John Guillebaud, medical director of the Margaret Pyke Family Planning Centre in London, says the pills will be available to "fully informed" women, with risk factors for arterial blood disease which increases their chance of heart attack and stroke.
Writing in the the British Medical Journal, he says that new studies which triggered the alert confirm the "amazing safety of all modern formulations of the combined pill with regard to ... venous thrombo-embolism [clots in the veins]." The danger, even with the "risky" pills is half that of a clot in pregnancy. Other data shows the pills protect against heart attack and stroke
In the same issue, Professor Walter Spitzer, lead investigator of one of the studies, accused the Government of "misusing and misinterpreting" unpublished data. The Committee on Safety of Medicines last week advised 1.5 million women taking seven brands of the combined Pill, containing the synthetic progestogen hormones, desogestrel or gestodene, to change brands. Three independent studies have shown that they have twice the risk of blood clots as brands containing different progestogens.
Professor Guillebaud agrees with the CSM, however, that overweight women, those with varicose veins, a family history of blood clots, and those who are immobile should not be given Pills containing desogestrel or gestodene. Women under 30 will also be offered other brands.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments